Sonnet Biotherapeutics Holdings Inc (SONN) Live Share Price, Invest From India

Sonnet Biotherapeutics Holdings Inc Stock Performance

as on December 3, 2025 at 2:29 am IST

Day's Low
Day's High
$1.26
Day's Price Range
$3.16
$1.27
0.79%
Downside
148.82%
Upside
52 Week's Low
52 Week's High
$1.08
52-Week Price Range
$19.3
$1.27
14.96%
Downside
1419.69%
Upside

Sonnet Biotherapeutics Holdings Inc share price movements today

Previous Close: $3.10
Open: $3.15
Volume: 11.4M
Day's Low - High: $1.26 - $3.16
52 Week Low - High: $1.08 - $19.3

Sonnet Biotherapeutics Holdings Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Sonnet Biotherapeutics Holdings Inc Stock Fundamentals & Key Indicators

Check Sonnet Biotherapeutics Holdings Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

0.00%

Sonnet Biotherapeutics Holdings Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Sonnet Biotherapeutics Holdings Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Sonnet Biotherapeutics Holdings Inc	BUY	$-	NA	NA	0.00%
Insmed Incorporated	BUY	$44.1B	415.15%	-16.34	-264.83%
Alnylam Pharmaceuticals, Inc.	BUY	$61.4B	265.31%	1408.88	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$111.1B	102.84%	29.93	31.35%
Regeneron Pharmaceuticals, Inc.	BUY	$78.6B	46.95%	17.98	32.13%

Analyst Recommendation on Sonnet Biotherapeutics Holdings Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Sonnet Biotherapeutics Holdings Inc. Average target price of $20

Sonnet Biotherapeutics Holdings Inc Share Price Target

Get share price movements and forecasts by analysts on Sonnet Biotherapeutics Holdings Inc.

What analysts predicted

93.65%UPSIDE

Target Price

$20

Current Price

$1.27

Analyzed by

10 Analysts

Target

$20.00

Sonnet Biotherapeutics Holdings Inc target price $20, a slight upside of 93.65% compared to current price of $1.27. According to 10 analysts rating.

Sonnet Biotherapeutics Holdings Inc Stock’s Investor Sentiment and Interest

Investment in Sonnet Biotherapeutics Holdings Inc Shares on INDmoney has grown by 111.76% over the past 30 days, indicating increased transactional activity.

Time period: November 5, 2025 to December 5, 2025

Change:111.76% versus previous 30 day period

Search interest for Sonnet Biotherapeutics Holdings Inc Stock has increased by 521% in the last 30 days, reflecting an upward trend in search activity.

Time period: November 5, 2025 to December 5, 2025

Change:521% versus previous 30 day period

Sonnet Biotherapeutics Holdings Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	0	0	0	0	-	-	0	1	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-5	-3	-3	-1	0	-3	-3	-3	-3	-3
Net Profit Margin	-15549.46%	-10710.29%	-9869.12%	-6273.54%	0.00%	0.00%	-2996.97%	-316.07%	0.00%	0.00%

Sonnet Biotherapeutics Holdings Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Sep 2020	Dec 2020	Sep 2021	Dec 2021	Sep 2022	Dec 2022	Sep 2023	Dec 2023	Sep 2024
Total Revenue	40	-	-	0	0	0	0	0	0	0
Gross Profit	32	0	-	0	-	-21	-	0	-	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-5	-24	-31	-25	-25	-29	-29	-18	-18	-7
Net Profit Margin	-12.40%	0.00%	0.00%	-5170.52%	-5170.52%	-8508.34%	-8508.34%	-12741.58%	-12741.58%	-39929.30%

Global Institutional Holdings in Sonnet Biotherapeutics Holdings Inc

Funds	Holdings
Mmcap International Inc. Spc	1.96%
Geode Capital Management, LLC	0.36%
XTX Topco Ltd	0.2%
UBS Group AG	0.1%
Tower Research Capital LLC	0.02%

See all

Insights on Sonnet Biotherapeutics Holdings Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 18.62K → 1.0M (in $), with an average increase of 85.9% per quarter
NO EFFECT
Against Peers
In the last 1 year, Insmed Incorporated has given 174.2% return, outperforming this stock by 211.8%
NO EFFECT
Against Peers
In the last 3 years, Insmed Incorporated has given 914.2% return, outperforming this stock by 1013.5%
NEGATIVE IMPACT
Price Dip
In the last 7 days, SONN stock has moved down by -69.7%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 4 quarters, -3.12M → -3.77M (in $), with an average decrease of 6.5% per quarter

About Sonnet Biotherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Organisation	Sonnet Biotherapeutics Holdings Inc
E-voting on shares	Click here to vote

FAQs

What is Sonnet Biotherapeutics Holdings Inc share price today?

Sonnet Biotherapeutics Holdings Inc share price today is $1.27 as on December 3, 2025 at 2:29 am IST at the close of the market. Sonnet Biotherapeutics Holdings Inc share today touched a day high of $3.16 and a low of $1.26.

What is the 52 week high and 52 week low for Sonnet Biotherapeutics Holdings Inc share?

Sonnet Biotherapeutics Holdings Inc share touched a 52 week high of $19.3 on July 14, 2025 and a 52 week low of $1.08 on May 27, 2025. Sonnet Biotherapeutics Holdings Inc stock price today i.e. December 3, 2025 at 2:29 am IST is closed at $1.27,which is 93.42% down from its 52 week high and 17.59% up from its 52 week low.

How to invest in Sonnet Biotherapeutics Holdings Inc Stock (SONN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Sonnet Biotherapeutics Holdings Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sonnet Biotherapeutics Holdings Inc Shares that will get you 1.1811 shares as per Sonnet Biotherapeutics Holdings Inc share price of $1.27 per share as on December 3, 2025 at 2:29 am IST.

What is the minimum amount required to buy Sonnet Biotherapeutics Holdings Inc Stock (SONN) from India?

Indian investors can start investing in Sonnet Biotherapeutics Holdings Inc (SONN) shares with as little as ₹89.888 or $1 (as of December 5, 2025 at 7:09 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹898.88 in Sonnet Biotherapeutics Holdings Inc stock (as per the Rupee-Dollar exchange rate as on December 5, 2025 at 7:09 am IST). Based on Sonnet Biotherapeutics Holdings Inc share’s latest price of $1.27 as on December 3, 2025 at 2:29 am IST, you will get 7.8740 shares of Sonnet Biotherapeutics Holdings Inc. Learn more about fractional shares .